Menu Back to DIA-Advancing-Complex-Innovative-Clinical-Trial-Designs-to-Efficiently-Deliver-Medicines-to-Patients

Overview

NEW CONFERENCE

Co-sponsored with the FDA

Complex Innovative Trial Designs (CID) have the potential to increase the efficiency and lower the cost of drug development which will accelerate patient access to life-altering therapies. The 21st Century Cures Act (Cures Act) and the sixth iteration of the Prescription Drug User Fee Act (PDUFA VI) recognize the need for CID and include provisions to advance their use to enhance medical product development. One such provision within PDUFA VI is the launch and implementation of the FDA CID Pilot Meeting Program which aims to foster discussions and education of the use and value of CID within drug development programs.

In an effort to promote CID, the unique conference will provide a platform for extensive scientific exchange among the FDA, other global health authorities including EMA, PMDA, and CFDA, patient advocates, and drug development innovators on CID topics such as master protocols, complex adaptive design, and Bayesian techniques, highlighting also the potential of alternative data sources.

Each session will begin with an introductory presentation by an FDA representative to set the stage followed by presentations and perspectives from a diverse group of expert speakers and panelists. The suitability of each CID topic and the proposed innovations from a US and global regulatory perspective, their usefulness from a patient perspective, and how challenges in the designs can be overcome, will be explored.

This conference is designed for key drug development decision-makers including clinicians, regulatory scientists and reviewers, and other key stakeholders, in addition to statistical specialists. Join us in this unique forum that will catalyze progress in advancing innovation in drug development.

The program is developed in collaboration with BIO, PhRMA and FDA.

The program has been released! Preview all session descriptions, speakers, and more all in one place!
View Program.


Who should attend?

Professionals involved in:

  • Biostatistics, including Adaptive Design and Bayesian Statistics
  • Clinical Research
  • Research and Development
  • Trial Design
  • Clinical Operations
  • Therapeutic Area Development, Management, and Operationist
  • Rare disease, oncology, immunology, Alzheimer’s disease
  • Medical Affairs
  • Medical Science Liaisons
  • Medical Writing
  • Regulatory Affairs

Learning objectives

At the end of this conference participants should be able to:
  • Explain how complex innovative clinical trial designs (CIDs) contribute to increased efficiency and other enhancements of medical product research in order to ultimately accelerate patient access to innovative therapies
  • Describe the purpose, anticipated outcomes, and progress to date of the FDA CID Pilot Program
  • Discuss the views of global regulatory authorities (e.g., FDA, EMA, PMDA, and NMPA) on CIDs and their suitability/applicability for clinical research in their respective regions
  • Explore aspects and further opportunities for alignment among global regulatory agencies in regard to CID adoption
  • Examine several examples of CIDs, including master protocol designs, complex adaptive designs, and designs using Bayesian techniques, and discuss their regulatory suitability, potential challenges, and benefits for patients and medical product developers

Program Committee

  • Robert A. Beckman, MD
    Robert A. Beckman, MD Professor of Oncology, Biostatistics, Bioinformatics, & Biomathematics
    Georgetown University Medical Center, United States
  • Fanni  Natanegara, PhD
    Fanni Natanegara, PhD Principal Research Scientist
    Eli Lilly and Company, United States
  • Zoran  Antonijevic, MSc
    Zoran Antonijevic, MSc Head of Biometrics
    MedSource, United States
  • Cristiana  Mayer, DrSc, PhD
    Cristiana Mayer, DrSc, PhD Director, Statistics and Decision Sciences
    Janssen Research & Development, LLC, United States
  • Dionne  Price, PhD
    Dionne Price, PhD Director, Division of Biometrics IV, Office of Biostatistics, OTS, CDER
    FDA, United States
  • Karen Lynn Price, PhD
    Karen Lynn Price, PhD Research Fellow, Statistical Innovation Center
    Eli Lilly and Company, United States
  • Pritibha  Singh, MBA, MSc, PMP
    Pritibha Singh, MBA, MSc, PMP
    Novartis, Switzerland
  • Rui  Tang
    Rui Tang Head of US Biostats & Programming Department&Medical Writing
    Servier Pharmaceuticals, United States
  • Amy  Xia, PhD
    Amy Xia, PhD Vice President, Biostatistics, Design & Innovation
    Amgen Inc., United States
  • Maria  Apostolaros, JD, PharmD, MS, RPh
    Maria Apostolaros, JD, PharmD, MS, RPh
    PhRMA, United States
  • Yi  Liu, PhD
    Yi Liu, PhD Senior Director Biostatistics
    Nektar Therapeutics, United States
Load More

Contact us

Registration Questions?

Send Email
1.888.257.6457


Additional Information

Complex Innovative Clinical Trial Designs Resource Kit


View Infographic


On Demand Content Preview Webinar

Recent Regulatory Efforts on Complex Innovative Clinical Trial Design
Register Today!


Digital Learning Catalog

DIA Learning: eLearning Soultions
Download